42 results about "Right atrial" patented technology

The invention discloses a foaming test device and system. According to the foaming test device, left / right atrial angiography tests can be taken into consideration at the same time, and when the foaming test device is switched into the left atrial angiography working mode, normal saline and a contrast agent can be automatically mixed to form a left atrial angiography mixed solution, and a left atrial angiography foaming solution is further formed; when the foaming test device is switched into a right atrial angiography working mode, normal saline, air and blood can be automatically mixed to form a right atrial angiography mixed solution, and a right atrial angiography foaming solution is further formed; the first injector and the second injector are matched with each other to perform reciprocating injection, so that the foaming efficiency of the left / right atrial angiography mixed liquid can be effectively improved, the time for forming the bubble liquid is shortened, automatic preparation of the left / right atrial angiography bubble liquid is quickly realized, meanwhile, the quality, preparation efficiency and consistency of the bubble liquid can be improved, and the production cost is reduced. And the accuracy of auxiliary screening is improved.

The utility model provides a rapid non-exchange puncturing and conveying system for heart patent foramen ovale plugging. The rapid non-exchange puncturing and conveying system comprises a conveying sheath body and an expansion inner core. The conveying sheath body comprises a sheath head section, a bending adjusting section, a pipe body section and a connector section which are sequentially arranged. The total length of the sheath head section and the bending adjusting section is 2-3 cm, the length of the bending adjusting section is 0.5-1 cm, and the bending degree of the bending adjusting section is adjustable. The expansion inner core is arranged in the conveying sheath body in a penetrating mode. The conveying sheath body, the expansion core and the plugging device assembly system can smoothly complete the conveying sheath to enter the left atrium through the patent foramen ovale and complete the plugging device release operation, particularly, the bending adjusting section is designed to be adjustable in bending, the conveying sheath is more suitable for right atrium operation of different forms, the instrument exchange step in the existing operation process is reduced, and the operation efficiency is improved. The risk that an atrium and an atrial appendage are damaged by an existing material is reduced, the operation time can be remarkably shortened, and a very simple patent foramen ovale plugging operation is achieved.

The invention provides a self-adaptive control method and device for a double-ventricle auxiliary system. The method comprises the steps that target aortic pressure detected by a first pressure sensor, target left ventricular end diastolic pressure detected by a second pressure sensor, target right atrial pressure detected by a third pressure sensor and target pulmonary artery pressure detected by a fourth pressure sensor are obtained; and determining a strategy for adjusting the left ventricular assist device or the right ventricular assist device according to the target left ventricular end diastolic pressure, the target right ventricular pressure and the target pulmonary arterial pressure when the peripheral perfusion of the target user is insufficient or the lung is over-perfused. The pressure sensors are arranged to detect the pressure of the inlets and the outlets of the left ventricular assist device and the right ventricular assist device, whether adverse events such as peripheral insufficiency or pulmonary hyperperfusion occur to a user or not is judged according to the detected pressure, and then the adverse events are relieved or even solved by adjusting the rotating speeds of the left ventricular assist device and the right ventricular assist device. And the safety of the user is greatly improved.

The utility model relates to an adult simulation load device for online calibration of an extracorporeal membrane oxygenation system. The system comprises a left ventricular artery system simulation box, a right atrial vein system simulation box, a resistance device, a V-A ECMO treatment mode artery perfusion cannula, a V-V ECMO treatment mode vein perfusion cannula, a vein drainage cannula, a bottom plate, a right atrial vein system simulation box hydraulic monitoring sensor, a left ventricular artery system simulation box hydraulic monitoring sensor and a manual pressure release valve. And a ball valve pressurizing device and a vertical partition plate. The left ventricular artery system simulation box, the resistance device and the right atrial vein system simulation box are sequentially connected through pipelines. The device is simple in structure, convenient and practical to operate and capable of accurately simulating the blood volume of a patient, the pressure difference between a venous system and an arterial system and the resistance of a blood circulation system when an adult patient adopts a V-A ECMO treatment mode and a V-V ECMO treatment mode respectively, and has practical value; calibration data has clinical guiding significance, the measurement accuracy of key parameters of equipment is effectively guaranteed, and clinical risks are reduced.

A method of right atrial pacing of a heart of a patient includes the steps of: stimulating right atrial tissue of the heart using a right atrial lead of a dual chamber cardiac pacemaker to pace the heart with a stimulus architecture protocol; and stimulating local sympathetic and / or parasympathetic tissues with the stimulus architecture protocol proximate to the paced right atrial tissue causing nervous system activity that inhibits the autonomous nervous system to reduce blood pressure. A closed loop system operating according to this method and a cardiac pacing lead for implementing this method also are included within the scope of the illustrated embodiments.

VfA cardiac therapy uses an implantable medical device or system. The implantable medical device includes a tissue piercing electrode that is implanted from the Koch triangle area of the right atrium through the right atrial endocardium and the central fibrous body into the basal region and / or septal region of the left ventricular myocardium of the patient's heart. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be fully implanted within the patient's heart or one or more leads may be used to implant the electrodes into the patient's heart. The device may be used to provide cardiac therapy, including single chamber or multi-chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related therapy. Separate medical devices may be used to provide some of the functions for cardiac therapy, such as sensing, pacing, or shock therapy.

The invention discloses an interventional valve ring device and an interventional valve device. The interventional valve ring device and the interventional valve device can be used for mitral valve and tricuspid valve lesions. The interventional valve ring device is mainly composed of a valve ring, a valve ring conveying system, a fixing nail and a fixing nail conveying system. The interventional valve is mainly composed of a fixing support, a supporting support, a supporting support covering film and valve leaflets. The interventional valve ring and the interventional valve enter the heart through the interventional delivery system and can pass through the apex of the heart, the femoral vein, the jugular vein or the subclavian vein, the right atrium or the left atrium. The interventional valve is fixed in the interventional valve ring, and a minimally invasive, safe and effective treatment method can be provided for a patient.

Systems and methods are described for determining a fluid congestion status of a subject, the method being carried out by at least one processor executing operations comprising: receiving an initial right atrial pressure for the subject; causing, over a time period, a vessel occlusion device to perform an occlusion cycle to change blood flow resistance in a blood vessel of the subject; receiving monitored readings for a right atrial pressure response to the changed blood flow resistance in the blood vessel over the time period; and determining, for the subject and based on the readings representing the right atrial pressure response, a fluid congestion status associated with a heart of the subject.

Methods, systems, and computer-readable medium for determining a systemic vascular resistance (SVR), by receiving a systolic blood pressure (SBP) and a diastolic blood pressure (DBP) from one or more blood pressure devices, receiving a first bioimpedance from a first electrode and a second bioimpedance from a second electrode, determining a stroke volume based on a difference between the first bioimpedance and the second bioimpedance, determining a mean arterial pressure (MAP) based on the SBP and the DBP, receiving a heart rate, determining a cardiac output based on the heart rate and the stroke volume, determining a first value based on a right atrial pressure (RAP) or central venous pressure (CVP) and the map, determining a second value based on the first value and the cardiac output, and determining a SVR based on the second value and a factor.

Methods, systems, and computer-readable medium for determining a systemic vascular resistance (SVR), by receiving a systolic blood pressure (SBP) and a diastolic blood pressure (DPB) from a calibrated photoplethysmography (PPG) device, receiving a pulse transit time (PTT) from the PPG device, determining a stroke volume based on the PTT, determining a mean arterial pressure (MAP) based on the SBP and the DBP, receiving a heart rate, determining a cardiac output based on the heart rate and the stroke volume, determining a first value based on a right atrial pressure (RAP) or central venous pressure (CVP) and the map, determining a second value based on the first value and the cardiac output, and determining a SVR based on the second value and a factor.

An implantable medical system may provide atrioventricular synchronous pacing using the ventricular septal wall. The system may include a ventricular electrode coupled to an intracardiac housing or a first medical lead implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the left ventricle of the patient's heart and a right atrial electrode coupled to a leadlet or second medical lead to deliver cardiac therapy to or sense electrical activity of the right atrium of the patient's heart. A right ventricular electrode may be coupled to the intracardiac housing or the first medical lead and implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the right ventricle of the patient's heart.

An implantable medical device (IMD) (210) for managing therapy is provided that is couplable to a lead (220, 224) with an electrode (222, 232), a memory (294) configured to store program instructions and one or more processors (260). The one or more processors (260) can be configured to execute the program instructions to determine a sensed right atrium (RAs) event or a paced right atrial (RAp) event (RAs,p event) (412), determine a sensed right ventricle (RVs) event (414) by detecting a cardiac activity (CA) signal (402) reaches a threshold amplitude (410) and determine a maximum amplitude (420) in a determined period of time (418) after the CA signal (402) reaches the threshold amplitude (410), and determine an RAs,p-RVs interval (404) between the RAs,p event (412) and RVs event (414). The one or more processors (260) can also be configured to calculate an atrioventricular delay (AV) delay based on the RAs,p-RVs interval (404), and manage therapy, provided by the IMD (210), based on the AV delay that is calculated.

The present disclosure relates to AV synchronized VFA cardiac therapy. VfA cardiac therapy uses an implantable medical device or system. The implantable medical device comprises a tissue puncture electrode, and the tissue puncture electrode penetrates through the right atrium endocardium and the central fiber body from the Koch triangular area of the right atrium to be implanted into the basal area and / or the diaphragm area of the left ventricular myocardium of the heart of the patient. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be completely implanted within the patient's heart, or one or more leads may be used to implant the electrodes into the patient's heart. The device may be used to provide cardiac treatments, including single or multi-chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronous pacing, or tachycardia-related treatments. Separate medical devices may be used to provide some functionality for cardiac therapy, such as sensing, pacing, or shock therapy.

An ultrasound imaging system may receive ultrasound data of a heart, wherein the ultrasound data was acquired across at least a portion of a cardiac cycle of the heart. The ultrasound imaging system may generate strain measurements based, at least in part on the ultrasound data. The ultrasound imaging system may analyze, using a cardiotoxicity detection algorithm, at least the strain measurements to determine a cardiotoxicity level of the heart. In some examples, the cardiotoxicity detection algorithm comprises a support vector machine (SVM) model trained on one or more of left ventricular (LV) strain data, left atrial (LA) strain data, right ventricular (RV) strain data, or right atrial (RA) strain data. In some cases, the cardiotoxicity detection algorithm uses one or more global left ventricular (LV) strain curves as an input to determine the cardiotoxicity level of the heart.

VfA cardiac therapy uses an implantable medical device or system. The implantable medical device includes a tissue-piercing electrode implanted in the basal and / or septal region of the left ventricular myocardium of the patient's heart from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be implanted completely within the patient's heart or may use one or more leads to implant electrodes in the patient's heart. The device may be used to provide cardiac therapy, including single or multiple chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related therapy. A separate medical device may be used to provide some functionality for cardiac therapy, such as sensing, pacing, or shock therapy.

An implantable medical system may provide atrioventricular synchronous pacing using the ventricular septal wall. The system may include a ventricular electrode coupled to an intracardiac housing or a first medical lead implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the left ventricle of the patient's heart and a right atrial electrode coupled to a leadlet or second medical lead to deliver cardiac therapy to or sense electrical activity of the right atrium of the patient's heart. A right ventricular electrode may be coupled to the intracardiac housing or the first medical lead and implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the right ventricle of the patient's heart.

The invention discloses an auxiliary diagnosis device and method for abnormal heart blood flow and a storage medium. The auxiliary diagnosis device for the abnormal heart blood flow comprises a monitoring control module used for monitoring whether a patient to be detected executes a Valsalva action or not in real time, and if yes, a pulse signal is sent; the image acquisition module is used for acquiring an image sequence of the to-be-detected patient in a right atrium pressure rise period based on the pulse signal, and performing target ROI extraction on the image sequence to obtain a target image sequence for displaying the target ROI; the light spot recognition module is used for detecting a microbubble signal in the target ROI of each frame of target image in the target image sequence in real time and counting the number of microbubbles in the target ROI of each frame of target image; the decision module is used for generating a corresponding diagnosis suggestion based on the number of microbubbles in the target ROI of each frame of target image; the full-process automation is realized, and the accuracy of heart blood flow abnormality diagnosis is improved; the diagnosis time is shortened, and the diagnosis efficiency is improved.

An implantable medical device (IMD) for managing therapy is provided that can include a lead with an electrode, a memory configured to store program instructions and one or more processors. The one or more processors can be configured to execute the program instructions to determine a sensed right atrium (RAs) event or a paced right atrial (RAp) event (RAs,p event), determine a sensed right ventricle (RVs) event by detecting a cardiac activity (CA) signal reaches a threshold amplitude and determining a maximum amplitude in a determined period of time after the CA signal reaches the threshold amplitude, and determine an RAs,p-RVs interval between the RAs,p event and RVs event. The one or more processors can also be configured to calculate an atrioventricular delay (AV) delay based on the RAs,p-RVs interval, and manage therapy, provided by the IMD, based on the AV delay that is calculated.

The invention discloses a multifunctional electrophysiological electrode catheter, and relates to the field of medical auxiliary equipment. Comprising a catheter, an outer layer, a high-position right ventricular electrode, a His beam electrode, a right ventricular electrode, an element groove, a main circuit, a pace-making control module, a miniature signal amplifier, a miniature signal filter, an analog-to-digital converter, a digital signal processor, a main control signal processing unit, a data transmission interface and a navigation positioning system module. According to the invention, the high-position right atrial electrode, the His beam electrode and the right ventricle electrode are integrated through a single catheter, and synchronous mapping of the high-position right atrial electrode, the His beam electrode and the right ventricle electrode is realized respectively. The device has the functions of electrophysiological signal mapping and cardiac pacing, and is provided with an independent signal processing module, so that high precision and stability of signal acquisition and processing are ensured. The design of the catheter supports single-puncture-point operation. The navigation positioning module is combined with an electric field and magnetic field sensor to position the catheter in the heart cavity.

A pulmonary artery catheter system may include a port housing coupled to the catheter and supporting: a right ventricular port, a right atrial port, a pulmonary artery distal lumen, a balloon port, and a volume sensor port. A pulmonary artery catheter system may include a plurality of volume sensors positioned along a length of the catheter and in communication with the volume sensor port.

VfA cardiac treatment uses an implantable medical device or system. The implantable medical device includes a tissue puncture electrode, which is implanted in the basal region and / or septal region of the left ventricular myocardium of the patient's heart through the right atrial endocardium and the central fiber body from the Koch triangle of the right atrium. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be completely implanted in the patient's heart, or one or more leads may be used to implant the electrode into the patient's heart. The device can be used to provide cardiac treatment, including single-chamber or multi-chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related treatment. A separate medical device can be used to provide some functions for cardiac treatment, such as sensing, pacing, or electric shock therapy.

The engagement of the two atria via atrial pacing therapy is determined using one or more metrics based on monitored external electrical activity. For example, external electrical activity can be monitored during delivery of the atrial pacing therapy, right atrial and left atrial components can be generated based on the monitored external electrical activity, and one or more metrics can be generated based on the right atrial and left atrial components. One or more metrics can then be used to determine whether the atrial pacing therapy has biatrial engagement.

Systems and methods are described for modulating blood flow through a blood vessel by providing an implantable device implanted in the blood vessel, monitoring, pressure in the blood vessel, and in response to detecting when a first pressure in the blood vessel is above a first predefined pressure range, causing actuation of the implantable device to modulate the blood flow through the blood vessel or an adjacent blood vessel according to a first actuation cycle configured to maintain the first pressure within the first predefined pressure range. In addition, the systems and methods may, in response to detecting, when a second pressure is above a second predefined pressure threshold, cause switching of the implantable device to a second actuation cycle to alter the modulation of the blood flow through the blood vessel.

Systems and methods are described for modulating blood flow through a blood vessel by providing an implantable device implanted in the blood vessel, monitoring, pressure in the blood vessel, and in response to detecting when a first pressure in the blood vessel is above a first predefined pressure range, causing actuation of the implantable device to modulate the blood flow through the blood vessel or an adjacent blood vessel according to a first actuation cycle configured to maintain the first pressure within the first predefined pressure range. In addition, the systems and methods may, in response to detecting, when a second pressure is above a second predefined pressure threshold, cause switching of the implantable device to a second actuation cycle to alter the modulation of the blood flow through the blood vessel.

A method of right atrial pacing of a heart of a patient includes the steps of: stimulating right atrial tissue of the heart using a right atrial lead of a dual chamber cardiac pacemaker to pace the heart with a stimulus architecture protocol; and stimulating local sympathetic and / or parasympathetic tissues with the stimulus architecture protocol proximate to the paced right atrial tissue causing nervous system activity that inhibits the autonomous nervous system to reduce blood pressure. A closed loop system operating according to this method and a cardiac pacing lead for implementing this method also are included within the scope of the illustrated embodiments.

The application discloses a foaming test device and system. In the foaming test device, left / right atrial contrast test can be considered simultaneously. When the foaming test device is switched to a left atrial contrast working mode, physiological saline and a contrast agent are automatically mixed to form a left atrial contrast mixed liquid, and a left atrial contrast foaming liquid is further formed. When the foaming test device is switched to a right atrial contrast working mode, physiological saline, air and blood are automatically mixed to form a right atrial contrast mixed liquid, and a right atrial contrast foaming liquid is further formed. Through reciprocating injection of the first injector and the second injector, the efficiency of foaming of the left / right atrial contrast mixed liquid can be effectively improved, the time for forming the foaming liquid is shortened, automatic preparation of the left / right atrial contrast foaming liquid is rapidly realized, the quality, preparation efficiency and consistency of the foaming liquid are improved, and the accuracy of auxiliary screening is improved.

Automated evaluation of RAP via machine learning is described herein. In one implementation, a method includes: obtaining first video scan data including multiple first video frames of an IVC of a subject, the multiple first video frames including a first video frame of the IVC while the subject is at rest, and a second video frame of the IVC while the subject is inhaling; determining, using a first trained model, based at least on the multiple first video frames, that the first video scan data corresponds to a sniff test of the IVC of the subject; and predicting, using a second trained model, based at least on the multiple first video frames, a RAP of the subject.

The invention discloses a cardiopulmonary resuscitation external chest compression parameter optimization method based on thoracic fracture risk assessment and blood perfusion, which comprises the following steps: inputting different waveform parameters, performing simulated cardiopulmonary resuscitation external chest compression operation on a current simulated thorax, and collecting corresponding pressure values borne by the simulated thorax and displacement values of the simulated thorax at different moments; acquiring thoracic aorta pressure and right atrium pressure corresponding to the simulated thorax by using a CPR blood circulation model, and acquiring corresponding coronary artery perfusion pressure CPP; according to the obtained CPP and the elastic modulus, obtaining a profit-risk tradeoff index BRI corresponding to different waveform parameters; and determining an optimal waveform parameter according to the BRI. According to the method, the influence of mechanical pressing parameter change on the sternum fracture risk and blood perfusion is explored, the judgment on the comprehensive pressing effect is obtained through comprehensive calculation, the blank of pressing waveform exploration in the American heart association guide is filled, and referable optimal pressing parameters and optimal pressing frequency are provided for clinical pressing.

This invention discloses a systemic circulation venous simulation system, comprising a right ventricular simulation component, an arterial compliance simulation component, a venous vessel module, a damping module, a throttling valve, a collapsible venous segment, a venous compliance simulation component, a right atrial simulation component, a drive module, and a data acquisition module. The right ventricular simulation component simulates the pumping function of the right ventricle; the arterial compliance simulation component simulates the elastic energy storage characteristics of the arterial system; the venous vessel module includes a collecting chamber, a superior vena cava return vessel, an inferior vena cava return vessel, and a vena cava confluence conduit; the collapsible venous segment prevents excessive negative pressure in the venous system; the venous compliance simulation component reduces the impact of right atrial pressure fluctuations on the venous vessels; and the right atrial simulation component simulates the right atrial filling state through internal volume changes. This simulation system can be used for in vitro testing of vena cava intervention devices.

A pulmonary arterial catheter system may include a port housing coupled to a catheter and supporting: a right ventricular port, a right atrial port, a pulmonary artery distal lumen, a balloon port, and a volume sensor port. A pulmonary arterial catheter system may include a plurality of volume sensors positioned along a length of the catheter and in communication with the volume sensor ports.